KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Operations (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Cash from Operations data on record, last reported at 498000000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 14.81% year-over-year to 498000000.0; the TTM value through Dec 2025 reached 3631400000.0, up 837.19%, while the annual FY2025 figure was 3631400000.0, 837.19% up from the prior year.
  • Cash from Operations reached 498000000.0 in Q4 2025 per VRTX's latest filing, down from 1241400000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 1369800000.0 in Q3 2024 and bottomed at 3753600000.0 in Q2 2024.
  • Average Cash from Operations over 5 years is 672475000.0, with a median of 955850000.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: soared 670.76% in 2022, then tumbled 430.89% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 995000000.0 in 2021, then grew by 8.38% to 1078400000.0 in 2022, then crashed by 78.25% to 234600000.0 in 2023, then skyrocketed by 149.19% to 584600000.0 in 2024, then decreased by 14.81% to 498000000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 498000000.0 in Q4 2025, 1241400000.0 in Q3 2025, and 1073100000.0 in Q2 2025.